Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-10-01
1999-12-07
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540504, 540509, C07D84324, A61K 31395
Patent
active
059984074
ABSTRACT:
The present invention is directed to substituted benozdiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
REFERENCES:
patent: 5532359 (1996-07-01), Marsters et al.
patent: 5550126 (1996-08-01), Horwell et al.
patent: 5578629 (1996-11-01), Ciccarone et al.
patent: 5595990 (1997-01-01), Baldwin et al.
patent: 5618812 (1997-04-01), Castro Pineiro et al.
patent: 5631251 (1997-05-01), Butcher et al.
patent: 5852010 (1998-12-01), Grahma et al.
Gibbs, J.B. et al., "Selective Inhibition of Farnesyl-Protein Transferase Blocks Ras Processing in Vivo," The Journal of Biological Chemistry, vol. 268, No. 11, pp. 7617-7620 (1993).
Graham, S.L., "Inhibitors of protein farnesylation: a new approach to cancer chemotherapy," Exp. Opin. Ther. Patents vol. 5 (12), pp. 1269-1285 (1995).
Graham, S.L. and Williams, Theresa M., "Inhibitors of protein franesylation," Exp. Opin. ther. Patents, vol. 6 (12), pp. 1295-1304 (1996).
James, G.L. et al., "Benzodiazepine Peptidomimetic BZA-5B Interrupts the MAP Kinase Activation Pathway in H-Ras-transformed Rat-1 Cells, but Not in Ultransformed Cells," The Journal of Biological Chemistry, vol. 269, No. 44, pp. 27705-27714 (1994).
James, G. L. et al., "Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells," Science, vol. 260 pp. 1937-1942 (1993).
James, G., et al., "Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro," The Journal of Biological Chemistry, vol. 270, No. 11, pp. 6221-6226 (1995).
Kohl, N.E. et al., "Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor", Science, vol. 260, pp. 1934-1937 (1993).
Kohl, N.E. et al.,"Protein farnesyltrasferase inhibitors block the growth of ras-dependent tumors in nude mice", Proc. Natl. Acad. Sci. USA, Med Sciences, vol. 91, pp. 9141-9145 (1994).
Kohl, N.E., et al., "Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice," Nature Medicine, vol. 1, No. 8, pp. 792-797 (1995).
Marsters, J.C., et al., "Benzodiazepine Peptidomimetic Inhibitors of Farnsyltransferase," Bioorganic & Medicinal Chemistry, vol. 2, No. 9, pp. 949-957 (1994).
Sepp-Lorenzino L., et al., "A Peptidomimetic Inhibitor of Farnesyl:Protein Transferase Blocks the Anchorage-dependent and-independent Growth of Human Tumor Cell Lines," Cancer Research, vol. 55, 5302-5309 (1995).
Anthony Neville J.
Graham Samuel L.
Wai John S.
Daniel Mark R.
Merck & Co. , Inc.
Pecoraro Dianne
Rao Deepak R.
Shah Mukund J.
LandOfFree
Inhibitors of farnesyl-protein transferase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of farnesyl-protein transferase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of farnesyl-protein transferase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-823996